Are you Niels Brueggemann?

Claim your profile

Publications (4)4.22 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this retrospective study we analyzed our experience with mucoepidermoid carcinoma (MEC) of the salivary glands and compared our results with those reported in the literature. A total of 42 patients were treated between January 1983 and December 2002 at the Department of Oral and Maxillofacial Surgery, Hanover Medical School. Thirty-three tumors were classified as low grade carcinomas, 9 tumors as high grade carcinomas. Tumor sites were the parotid gland in 11 cases, sublingual and submandibular gland in 6 cases, oral cavity and oropharynx in 22 cases and nasal cavity and maxillary sinus in 3 cases. There were 23 T1-, 6 T2-, 5 T3- and 8 T4-tumors with 35 N0-, 5 N1- and 2 N2-necks, all M0 at presentation. Resection remained incomplete for 9 patients. Six patients received postoperative radiation. Overall survival rates, overall local control rates and overall regional control rates at 5 and 10 years were 79.1% and 65.5%, 89.1% and 80.8%, 92.3% and 87.7%. None of our patients developed distant failure. Grade, stage and margin status significantly influenced prognosis. MEC is a rare tumor entity and should be treated in specialist centres within randomised prospective multicentric trials.
    Oral Oncology 02/2005; 41(1):3-10. · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this retrospective study we give a clinical review of our experience with different subtypes of salivary gland cancer. Between January 1983 and December 2002, a total of 155 patients with carcinomas of the salivary glands received initial treatment at the Department of Oral and Maxillofacial Surgery, Hanover Medical School. There were 79 (51.0%) adenoid cystic carcinomas, 42 (27.1%) mucoepidermoid carcinomas, 12 (7.7%) adenocarcinomas, 10 (6.5%) polymorphous adenocarcinomas and 12 (7.7%) other tumor entities of smaller number. Complete resection was reached for 63.5% of patients with high grade carcinomas and for 80.0% of patients with low grade carcinomas. 26.2% of patients with high grade carcinomas and 13.3% of patients with low grade carcinomas received postoperative radiation. Overall survival rates at 5, 10 and 15 years were 65.9, 48.0 and 39.8% with significant difference for patients with high grade and low grade carcinomas. Histopathologic subtype, tumor stage and margin status significantly influenced prognosis. Statistically, we were not able to demonstrate a positive effect for postoperative radiation. In the future, patients with salivary gland carcinomas should be randomised for prospective multicentric clinical trials, which could provide reliable information about adjuvant treatment modalities and their results even for rare subtypes of salivary gland cancer.
    International Journal of Oral and Maxillofacial Surgery 08/2004; 33(5):423-32. · 1.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this retrospective study we give a clinical review of our experience with different tumor entities of salivary gland cancer. Between January 1983 and December 2002, a total of 155 patients with carcinomas of the salivary glands received initial treatment at the Department of Oral and Maxillofacial Surgery, Hanover Medical School. There were 51.0% adenoid cystic carcinomas, 27.1% mucoepidermoid carcinomas, 7.7% adenocarcinomas, 6.5% polymorphous adenocarcinomas, and altogether 7.7% other less frequent tumor entities. Complete resection was achieved for 63.5% of patients with high-grade carcinomas and for 80.0% of patients with low-grade carcinomas. Postoperative radiation was administered to 26.2% of patients with high-grade carcinomas and 13.3% of patients with low-grade carcinomas. Overall local control rates at 5, 10, and 15 years were 77.5%, 66.2%, and 59.0%. Overall regional control rates at 5, 10, and 15 years were 93.5%, 87.6%, and 85,4%. Overall distant control rates at 5, 10, and 15 years were 85.9%, 77,2%, and 73,6%. Overall survival rates at 5, 10, and 15 years were 65,9%, 48,0%, and 39,8%. There was a significant difference between patients with low-grade and high-grade carcinomas. Polymorphous adenocarcinomas showed the best prognosis, followed by low-grade mucoepidermoid carcinomas, adenoid cystic carcinomas, adenocarcinomas, and high-grade mucoepidermoid carcinomas. The number of the remaining tumor entities was too small to be divided into independent subgroups for statistical analysis. Tumor entity, tumor stage, and margin status significantly influenced prognosis. Statistically, we were not able to demonstrate a positive effect for postoperative radiation. Grading is important, but should be considered in the context of stage. In the future, patients with salivary gland carcinomas should be randomized for prospective multicenter clinical trials, which could provide reliable information about adjuvant treatment modalities and their results even for rare subtypes of salivary gland cancer.
    Mund- Kiefer- und Gesichtschirurgie 06/2004; 8(3):191-201.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ziel dieser Untersuchung war, unsere langjährigen Erfahrungen mit verschiedenen Tumorentitäten der Speicheldrüsenkarzinome zu analysieren.Retrospektiv wurden 155 Patienten mit Speicheldrüsenkarzinomen erfasst, welche zwischen Januar 1983 und Dezember 2002 in der Klinik für Mund-, Kiefer- und Gesichtschirurgie der Medizinischen Hochschule Hannover behandelt worden waren.An adenoid-zystischen Karzinomen war 1,0% unserer Patienten erkrankt, 27,1% litten an Mukoepidermoidkarzinomen, 7,7% an Adenokarzinomen, 6,5% an polymorphen Adenokarzinomen und insgesamt 7,7% an weiteren Tumorentitäten mit geringeren Fallzahlen. Eine R0-Resektion wurde für 63,5% der Patienten mit hochmalignen Tumoren und für 80,0% der Patienten mit niedrigmalignen Tumoren erzielt. 26,2% der Patienten mit hochmalignen Tumoren und 13,3% der Patienten mit niedrigmalignen Tumoren erhielten eine postoperative Bestrahlung. Für das Gesamtkollektiv lagen die lokale Tumorkontrolle nach 5, 10 und 15 Jahren bei 77,5%, 66,2% und 59,0%, die regionale Tumorkontrolle nach 5, 10 und 15 Jahren bei 93,5%, 87,6% und 85,4%, die Fernmetastasenkontrolle nach 5, 10 und 15 Jahren bei 85,9%, 77,2% und 73,6% und die Überlebensrate nach 5, 10 und 15 Jahren bei 65,9%, 48,0% und 39,8%. Es gab einen signifikanten Unterschied zwischen niedrig- und hochmalignen Tumoren. Die beste Prognose zeigten polymorphe Adenokarzinome, gefolgt von niedrigmalignen Mukoepidermoidkarzinomen, adenoid-zystischen Karzinomen, Adenokarzinomen und hochmalignen Mukoepidermoidkarzinomen. Die Fallzahlen der übrigen Tumorentitäten waren zu gering, um eigene Untergruppen für statistische Auswertungen bilden zu können. Tumorentität, Tumorstadium und Resektionsstatus hatten einen signifikanten Einfluss auf die Prognose. Ein positiver Effekt für eine postoperative Bestrahlung konnte statistisch nicht nachgewiesen werden.Die Einteilung verschiedener Tumorentitäten nach ihrem Malignitätsgrad erweist sich aus prognostischer Sicht als sinnvoll, muss aber vor dem Hintergrund des Tumorstadiums betrachtet werden. Patienten mit Speicheldrüsenkarzinomen sollten zukünftig für prospektive randomisierte Studien multizentrisch erfasst werden, um die Wirksamkeit adjuvanter Behandlungsmodalitäten auch für seltene Tumorentitäten bestimmen zu können.
    Mund- Kiefer- und Gesichtschirurgie 01/2004; 8(3).